FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040287577> ?p ?o ?g. }

• W2040287577 endingPage "312" @default.
• W2040287577 startingPage "302" @default.
• W2040287577 abstract "Purpose: Acidic fibroblast growth factor (aFGF) is a potent mitogen for vascular and other mesenchymal cells in vitro that can induce angiogenesis in vivo. Although heparin has no mitogenic potential of its own, it is an important aFGF cofactor in vitro and may also be capable of stimulating angiogenesis. Because the development of a collateral vasculature in response to ischemia appears to be dependent on angiogenesis, we compared the abilities of aFGF with or without heparin and heparin alone to accelerate angiogenesis in a rat hind limb ischemia model.Methods: Daily subcutaneous injections of saline solution (1 ml), heparin (0.05 mg), or human recombinant aFGF with or without heparin (1 μg aFGF, 0.05 mg heparin) were administered into the hind limb region distal to the point of unilateral femoral artery ligation in the rat for the 10 days immediately after vascular occlusion. Angiogenicity was determined by histologic assessment of treatment outcomes.Results: Histologic assessment of the number of vessels per microscopic field 10 days after vascular ligation in the fibrofatty tissues distal to the ligation point had the following results: saline solution, 10 ± 4 vessels; heparin, 13 ± 4 vessels (p < 0.05 vs saline solution); aFGF, 26 ± 8 vessels; and aFGF/heparin 36 ± 8 vessels (aFGF, aFGF/heparin, p < 0.001 vs saline solution). Similar increases in vascularization were also noted in the skeletal muscle tissues distal to the vascular ligation point. Immunohistochemical analysis for the presence of proliferating cell nuclear antigen, a marker for mitogenic activity, demonstrated corresponding increases in proliferating cell nuclear antigen labeling for each of the treatment groups, expressed as a percentage of total vascular cell nuclei, as follows: saline solution, 7% ± 2%; heparin, 21% ± 8% (p < 0.05 vs saline solution); aFGF, 67% ± 9%; and aFGF/heparin, 83% ± 5% (aFGF, aFGF/heparin, p < 0.001 vs saline solution).Conclusions: The increased vascularization and mitogenic activity demonstrated by these respective studies suggest that angiogenesis is significantly accelerated by the administration of heparin alone and is accelerated to a greater extent by the administration of aFGF with or without heparin. The aFGF/heparin regimen may represent an optimal means of augmenting collateral vessel growth to relieve ischemia in the clinical setting. (J Vasc Surg 1997 26:302-12.)" @default.
• W2040287577 created "2016-06-24" @default.
• W2040287577 creator A5029163803 @default.
• W2040287577 creator A5038388427 @default.
• W2040287577 creator A5041785614 @default.
• W2040287577 creator A5046965699 @default.
• W2040287577 creator A5055250086 @default.
• W2040287577 creator A5080954657 @default.
• W2040287577 date "1997-08-01" @default.
• W2040287577 modified "2023-10-18" @default.
• W2040287577 title "Therapeutic angiogenesis: A comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin" @default.
• W2040287577 cites W1871642698 @default.
• W2040287577 cites W1964469715 @default.
• W2040287577 cites W1964537647 @default.
• W2040287577 cites W1972855766 @default.
• W2040287577 cites W1974472434 @default.
• W2040287577 cites W1974491777 @default.
• W2040287577 cites W1974636407 @default.
• W2040287577 cites W1974873948 @default.
• W2040287577 cites W1975991554 @default.
• W2040287577 cites W1976740313 @default.
• W2040287577 cites W1980408417 @default.
• W2040287577 cites W1986491860 @default.
• W2040287577 cites W1989157277 @default.
• W2040287577 cites W1991899977 @default.
• W2040287577 cites W1995453479 @default.
• W2040287577 cites W1999171451 @default.
• W2040287577 cites W2014128442 @default.
• W2040287577 cites W2020393611 @default.
• W2040287577 cites W2029231790 @default.
• W2040287577 cites W2038782636 @default.
• W2040287577 cites W2041467360 @default.
• W2040287577 cites W2046225265 @default.
• W2040287577 cites W2060260000 @default.
• W2040287577 cites W2061312392 @default.
• W2040287577 cites W2062972575 @default.
• W2040287577 cites W2063809780 @default.
• W2040287577 cites W2066457282 @default.
• W2040287577 cites W2070062282 @default.
• W2040287577 cites W2074259561 @default.
• W2040287577 cites W2080356707 @default.
• W2040287577 cites W2083241474 @default.
• W2040287577 cites W2092246905 @default.
• W2040287577 cites W2099395815 @default.
• W2040287577 cites W2099543104 @default.
• W2040287577 cites W2128749862 @default.
• W2040287577 cites W2133762215 @default.
• W2040287577 cites W2137061681 @default.
• W2040287577 cites W2162249561 @default.
• W2040287577 cites W2163938780 @default.
• W2040287577 cites W2408344606 @default.
• W2040287577 cites W4250806706 @default.
• W2040287577 cites W2046527404 @default.
• W2040287577 doi "https://doi.org/10.1016/s0741-5214(97)70193-9" @default.
• W2040287577 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9279319" @default.
• W2040287577 hasPublicationYear "1997" @default.
• W2040287577 type Work @default.
• W2040287577 sameAs 2040287577 @default.
• W2040287577 citedByCount "42" @default.
• W2040287577 countsByYear W20402875772012 @default.
• W2040287577 countsByYear W20402875772013 @default.
• W2040287577 countsByYear W20402875772015 @default.
• W2040287577 countsByYear W20402875772016 @default.
• W2040287577 countsByYear W20402875772017 @default.
• W2040287577 countsByYear W20402875772021 @default.
• W2040287577 countsByYear W20402875772023 @default.
• W2040287577 crossrefType "journal-article" @default.
• W2040287577 hasAuthorship W2040287577A5029163803 @default.
• W2040287577 hasAuthorship W2040287577A5038388427 @default.
• W2040287577 hasAuthorship W2040287577A5041785614 @default.
• W2040287577 hasAuthorship W2040287577A5046965699 @default.
• W2040287577 hasAuthorship W2040287577A5055250086 @default.
• W2040287577 hasAuthorship W2040287577A5080954657 @default.
• W2040287577 hasBestOaLocation W20402875771 @default.
• W2040287577 hasConcept C126322002 @default.
• W2040287577 hasConcept C142724271 @default.
• W2040287577 hasConcept C150903083 @default.
• W2040287577 hasConcept C170493617 @default.
• W2040287577 hasConcept C179437574 @default.
• W2040287577 hasConcept C207001950 @default.
• W2040287577 hasConcept C2775960820 @default.
• W2040287577 hasConcept C2777408375 @default.
• W2040287577 hasConcept C2777557582 @default.
• W2040287577 hasConcept C2777587049 @default.
• W2040287577 hasConcept C2778271429 @default.
• W2040287577 hasConcept C2780394083 @default.
• W2040287577 hasConcept C2781188250 @default.
• W2040287577 hasConcept C541997718 @default.
• W2040287577 hasConcept C71924100 @default.
• W2040287577 hasConcept C74373430 @default.
• W2040287577 hasConcept C86803240 @default.
• W2040287577 hasConceptScore W2040287577C126322002 @default.
• W2040287577 hasConceptScore W2040287577C142724271 @default.
• W2040287577 hasConceptScore W2040287577C150903083 @default.
• W2040287577 hasConceptScore W2040287577C170493617 @default.
• W2040287577 hasConceptScore W2040287577C179437574 @default.
• W2040287577 hasConceptScore W2040287577C207001950 @default.
• W2040287577 hasConceptScore W2040287577C2775960820 @default.

• next